The National Institutes of Health (NIH) has recently implemented a significant reduction in overhead funding for research grants, capping indirect costs at 15%, a sharp decrease aimed at reducing government spending by $4 billion and focusing federal dollars on direct research costs rather than administrative expenses. Indirect costs, cover the expenses associated with running research labs—such as utilities, lab equipment, and waste disposal.
However, these costs have ballooned in recent years. Institutions like Harvard, Yale, and Johns Hopkins, for instance, have been awarded indirect costs in excess of 60%. In a recent email, Mark T. Gladwin, MD, Dean, University of Maryland School of Medicine shared that UMB’s Indirect Cost Rate for FY 2024 was 55.5%, with total Indirect Costs of $49.5 million which would result in a projected taxpayer savings of $37.5 million with the new mandate – or a loss of $37.5 million from UMB’s perspective.
Critics cite that many of the most active foundation-based research grantors already cap their indirect costs at 15% so why shouldn’t Federally funded grants have the same cap to ensure that taxpayer money is being spent most efficiently.
While the intention behind these cuts is clear, and it’s probably well overdue for some serious auditing of University research spending and efficiency, many argue that these cuts fail to consider the role that indirect costs play in enabling successful research. Lab equipment and infrastructure are essential for carrying out the research that ultimately leads to medical breakthroughs.
For every $1 of research funding, the NIH generates $2.46 in economic activity, further highlighting the importance of well-funded research environments – but could that impact factor be even higher if the funding was applied more efficiently? That’s the question we may all find out if this mandate upholds.
Rather than simply criticizing the decision or taking a stance either way, I thought a more productive exercise would be to approach an exploration of alternative strategies that could help meet the new fiscal objectives, while also supporting universities in maintaining robust research environments and promoting continued investment in innovation.
Below are five performance-driven alternative models that incentivize universities to be more efficient and productive with the grant money they receive. Could any of these provide a middle ground option to land on?
1. Performance-Based Federal Funding Allocation
Drawing from corporate profit-sharing and performance bonus models, this strategy ties a portion of NIH funding to the commercialization and societal impact of university research. Universities could earn additional funding or “Commercialization Bonus Pool” allocations if they meet specific commercialization metrics, such as successful startup spinouts, licensing revenues, or patents leading to FDA-approved therapies.
How It Works:
- NIH could introduce a multiplier system where universities that generate significant commercialization revenue (e.g., $50M+) receive a funding boost of up to 10%.
- This system encourages universities to act like venture studios, focusing on translating research into marketable products and real-world health improvements.
Benefit:
By rewarding universities for their success in bringing research to market, this model fosters a closer relationship between government, academia and industry, ensuring more efficient use of taxpayer dollars and creating tangible societal benefits.
2. Federally Funded Research Matching with Industry Partnerships
To ensure that academic research translates to real-world solutions, this model incentivizes universities to build partnerships with the private sector. Universities that secure industry co-investment in their federally funded research would receive additional support, such as increased indirect cost recovery or direct commercialization funding.
How It Works:
- For every $1 co-invested by an industry partner, NIH could match $0.50–$1. This encourages universities to form strategic collaborations that accelerate research commercialization.
Benefit:
Like co-development partnerships in the private sector, this model aligns government funding with private investment, driving faster and more successful adoption of academic research into the market.
3. Performance-Based Indirect Cost Recovery Rates
Instead of a flat indirect cost rate for all universities, this strategy ties the rate to the institution’s commercialization success. Universities that demonstrate high-impact results—such as high licensing revenue, successful startup formation, and patents used in commercial applications—would be eligible for higher indirect rates, while those with low commercialization outcomes would receive lower indirect support.
How It Works:
- High-performing institutions could receive up to 50% in indirect costs, while others would only receive a baseline rate (e.g., 25%).
Benefit:
This creates a direct incentive for universities to focus on commercialization and research outcomes, aligning funding with actual results rather than just the prestige of the institution.
4. Cost-Effectiveness Innovation Challenges
NIH could introduce “Innovation Challenges” that encourage universities to find innovative ways to reduce costs while maintaining research quality. Universities could apply for additional funding or grants if they can demonstrate novel approaches to reducing bureaucracy or increasing research efficiency.
How It Works:
- Universities could compete for “Innovation Challenge” grants by submitting proposals outlining how they plan to reduce administrative inefficiencies, streamline operations, and better allocate research funds.
- Successful proposals could receive additional funding or support from NIH, with a focus on scaling successful efficiency models.
Benefit:
- Stimulates creativity and problem-solving within universities, driving them to develop new solutions for administrative inefficiencies.
- Promotes a culture of continuous improvement and fiscal responsibility.
5. Societal Impact Commercialization Score
Drawing inspiration from ESG (Environmental, Social, Governance) models, the NIH could introduce a “Societal Impact Score” that ranks universities based on their ability to generate real-world health and technological benefits. This score would be based on metrics such as FDA-approved therapies, medical devices used in hospitals, and technological innovations reaching industry.
How It Works:
- High-scoring universities would unlock more federal grants, higher indirect cost rates, and additional commercialization funding, while lower-scoring universities would receive targeted assistance and be required to demonstrate progress.
Benefit:
This system ensures that federal funding is directed toward institutions that are not just publishing papers but making tangible contributions to society. It also creates healthy competition between universities, driving them to focus on impactful research.
Can Incentivizing Impact Over Indirect Costs Work?
The NIH’s decision to limit indirect cost funding will undoubtedly reshape the landscape of federal research funding. While the 15% cap is intended to redirect resources to direct research costs, it risks stifling the infrastructure that enables groundbreaking discoveries. Instead of focusing solely on cutting overhead costs, the NIH could adopt these alternative strategies, which reward universities based on real-world impact, commercialization success, and industry partnerships.
By aligning federal funding with performance-driven outcomes, these are a few strategies that seek to offer a balanced approach, incentivizing universities to not only be efficient but also productive in translating research into tangible societal benefits. Through performance-based incentives, the NIH could encourage universities to act as catalysts for innovation, ultimately driving more impactful medical advancements while meeting the fiscal goals of the administration.
What other alternative models could you recommend?
